Chronic Hepatitis B, Liver Fibrosis
Conditions
Brief summary
This research puts liver biopsy as the enrollment screening criteria and the primary efficacy assessment indicators. Patients at different developmental stages of hepatitis B related liver fibrosis are respectively diagnosed and treated by Traditional Chinese medicine to determine optional diagnosis and treatment plan of traditional Chinese medicine to screen the advantage-treated population and to establish a treatment program, which can save national medical resources, for clinical application of Traditional Chinese medicine Diagnosis and Treatment blocking and reversing hepatitis B-related liver fibrosis. The research can help to build automation pathological analysis and diagnosis systems and non-invasive clinical assessment criteria and models of liver fibrosis which can be applied in clinical. It can also help to realize electronic patient data collection and management, to establish patients management centre and follow-up database. Then it will help to improve clinical efficacy of being blocked and reversed chronic hepatitis B related liver fibrosis by Chinese medicine Diagnosis and Treatment program, to reduce the incidence of liver cirrhosis and hepatitis B-related mortality, to prolong patients' survival and improve patients' quality of life, to make clinical efficacy, which is about Traditional Chinese Medicine blocking and revering chronic hepatitis B-related liver fibrosis, increase by 15% or more .
Interventions
DRUGFufang Biejia Ruangan Tablet
DRUGPlacebo
Sponsors
Beijing 302 Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
Inclusion criteria of chronic hepatitis B related liver fibrosis: 1. Age from 18 to 65 years old, male or female; 2. Consistent with the diagnosis criteria of chronic hepatitis B; 3. liver fibrosis(liver biopsy) stage F ≥ 3 (Ishak), HBV DNA ≥ 104 copies / ml (or ≥ 2000 IU / ml) were; 4. TCM syndrome type: blood stasis, blood deficiency with toxic heat retention; 5. Not taking over nucleoside antiviral in one year, no drug treatment of liver fibrosis in six months; 6. Signed informed consent.
Exclusion criteria
1. liver fibrosis(Liver biopsy) stage F \<3 (Ishak); 2. Combined with other severe chronic hepatitis, cirrhosis, liver cancer and other severe or end-stage liver disease; 3. Accompanied by uncontrollable heart, kidney, lung, endocrine, blood, metabolic and gastrointestinal serious primary disease; or mental illness; 4. Pregnant or lactating women; 5. Patients with allergic constitution or allergic to TCM used; 6. Not be prescribed medication, poor compliance, incomplete data affecting the efficacy and safety of those judgments; 7. Patients unsuitable for this trial in Researchers' consideration; 8. Co-infection with other viral liver disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Liver histological changes | before treatment and after 48 weeks twice |
Countries
China
Contacts
Primary ContactYongping Yang, Master
Outcome results
None listed